UPDATE: Morgan Stanley Raises PT on Biogen Idec on Long-Term Potential
March 25, 2013 at 13:18 PM EDT
In a report published Monday, Morgan Stanley analyst Marshall Urist reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB ), and raised the price target from $177.00 to $188.00. In the report, Urist noted, “We are positive on Tecfidera's long-term potential as 2015 consensus implies relatively conservative launch metrics, but
